Clinical Trials & Research
Search Clinical Trials
Clinical Trials
New Search
Title | A 24 Week, Multicenter, Randomized, Double-Blind, Parallel Group, Phase 3 Trial with a 28 Week Long Term Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 10 mg in T2DM Patients aged 10-24 years. |
---|---|
Disease/Condition | Pediatric Endocrinology |
Eligibility Criteria | Click here for eligibility requirements |
Principal Investigator | Rubina Heptulla |
Contact Name | Ranjitha Katikaneni |
Contact Email | rkatikan@montefiore.org |
IRB/Protocol Number | IRB# 16-10-255-01 |
Status | Enrolling |
Adult Clinical Trial | No |
Pediatric Clinical Trial | No |